Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eradication of Helicobacter pylori With Vonoprazan-Amoxicillin Dual Therapy as an Alternative for Bismuth-Based Quadruple Therapy: A Systematic Review and Noninferiority Meta-Analysis.

Journal of gastroenterology and hepatology·2026
Same author

Primary Sclerosing Cholangitis Recurrence After Liver Transplantation: A Systematic Review and Updated Meta-Analysis.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Early molecular patterns linked to subsequent graft dysfunction in kidney allografts with histologically normal surveillance biopsies.

Clinical transplantation and research·2026
Same author

Bringing the Teaching Close to Home: Implementation of a Near-Peer Model for Introductory Hematology-Oncology Fellowship Lecture Series.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026
Same author

Oral selective estrogen receptor degraders in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis.

Breast cancer research and treatment·2026
Same author

Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis.

Diabetes care·2026

Related Experiment Video

Updated: Jul 17, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Real-World Luspatercept Evidence in Myelodysplastic Neoplasms: A Systematic Review and Bayesian Meta-Analysis.

Pedro Robson Costa Passos1,2, Valbert Oliveira Costa Filho1, Roberto Cavalcante Venâncio1,2

  • 1Center of Research and Drug Development (NPDM), Federal University of Ceara, Fortaleza, Ceara, Brazil.

Hematological Oncology
|July 16, 2026
PubMed
Summary

This study synthesized real-world data on luspatercept for myelodysplastic neoplasms (MDS). Effectiveness metrics like hematologic improvement-erythroid (HI-E) and transfusion independence (TI) were analyzed, revealing modest differences compared to clinical trials.

Keywords:
Bayesianluspaterceptmeta‐analysismyelodysplastic neoplasmsreal‐world evidence

Related Experiment Videos

Last Updated: Jul 17, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Luspatercept is a treatment option for lower-risk myelodysplastic neoplasms (MDS).
  • Real-world effectiveness and safety data for luspatercept are limited.
  • Understanding luspatercept's performance outside clinical trials is crucial for patient care.

Purpose of the Study:

  • To synthesize real-world evidence (RWE) on luspatercept's effectiveness in adult MDS patients.
  • To evaluate the safety profile of luspatercept in real-world settings.
  • To compare RWE findings with data from controlled clinical trials.

Main Methods:

  • Systematic literature search adhering to PRISMA guidelines up to June 2025.
  • Bayesian random-effects meta-analyses of pooled clinical trial data and RWE.
  • Extraction of data on hematologic improvement-erythroid (HI-E), transfusion independence (TI), adverse events, and overall survival (OS).

Main Results:

  • Pooled HI-E rate was 46.6%; pooled TI rates at 8, 12, and 16 weeks were 44.7%, 38.6%, and 30.9%, respectively.
  • Higher TI and HI-E observed in patients with positive SF3B1 status and Asian patients.
  • Hypertension and falls were more common in RWE; real-world HI-E was modestly lower than in trials.

Conclusions:

  • Luspatercept demonstrates effectiveness in real-world MDS populations, though outcomes may be influenced by patient selection, adherence, and monitoring.
  • Disease, geographical, and demographic factors appear to moderate treatment response.
  • These real-world insights are vital for refining clinical decisions and future study designs.